First-line Durvalumab Improves Survival
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Four-Year Survival With Durvalumab After Chemoradiotherapy in Stage III NSCLC—an Update From the PACIFIC Trial - ScienceDirect
First-line Durvalumab Improves Survival
Durvalumab after Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer | NEJM
Stage III NSCLC - NSCLC Treatment Paradigm - Text Module - NSCLC Practical Guidance - Oncology - Clinical Care Options
Gerry Hanna 💙 on Twitter: "PACIFIC study - adjuvant Durvalumab demonstrates a major step change in the management of stage 3 NSCLC with a clear increase in OS #WCLC2018 @IASLC @BTOGORG #radonc @
Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial - The Lancet
Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC | NEJM
Design and Rationale for a Phase III, Double-Blind, Placebo-Controlled Study of Neoadjuvant Durvalumab + Chemotherapy Followed by Adjuvant Durvalumab for the Treatment of Patients With Resectable Stages II and III non-small-cell Lung
Outcomes with durvalumab by tumour PD-L1 expression in unresectable, stage III non-small-cell lung cancer in the PACIFIC trial - ScienceDirect
Durvalumab - Wikipedia
PACIFIC Trial Leads to Durvalumab Approval in United States - ILCN.org (ILCN/WCLC)
Decision making process diagram to evaluate candidate patients for... | Download Scientific Diagram
Durvalumab in non-small-cell lung cancer patients: current developments | Future Oncology
Three-Year Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC—Update from PACIFIC - Journal of Thoracic Oncology
Cancers | Free Full-Text | Real World Outcomes versus Clinical Trial Results of Durvalumab Maintenance in Veterans with Stage III Non-Small Cell Lung Cancer | HTML
PACIFIC phase III trial scheme. | Download Scientific Diagram
Immunotherapy: analyses elucidating durvalumab & pembrolizumab activity - memoinOncology
Rapid Readouts: Updated Results and 5-Year Survival Outcomes From the PACIFIC Trial
Durvalumab Improves 5-year OS and PFS in Patients With Unresectable Stage III NSCLC
Durvalumab in non-small-cell lung cancer patients: current developments. | Semantic Scholar
A Phase III Study of Durvalumab (MEDI4736) With or Without Tremelimumab for Previously Treated Patients With Advanced NSCLC: Rationale and Protocol Design of the ARCTIC Study - Clinical Lung Cancer
